97299 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell proliferation
Clec9A binding agents
#302Anti-human VISTA antibodies and use thereof
#303LAG-3 binding members
#304Agonistic antibodies that bind CD40
#305Anti-MET antibodies and uses thereof
#306Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#307Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
#308Anti-OX40 antibodies
#309Anti-PD1 and anti-CTLA4 antibodies
#310Anti-PD-1 antibodies
#311Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
#312Binding molecules binding PD-L1 and LAG-3
#313Anti-ICOS and anti-PD-1 antibody combination therapy
#314Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
#315Non-cytotoxic modified cells and use thereof
#316Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#317CD73 blocking agents
#318Anti-PD-L1 antibodies and variants
#319Chimeric poxvirus compositions and uses thereof
#320TRPM4 CHANNEL INHIBITORS FOR STROKE TREATMENT
#321BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#322Humanized Anti-CD134 (OX40) Antibodies And Uses Thereof
#323Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
#324Antibodies for Siglec-15 and methods of use thereof
#325Anti-CD277 antibodies
#326Anti-C10ORF54 antibodies and uses thereof
#327Fusion protein comprising apelin and an anti-APLNR antibody
#328Antibodies to TGF-β
#329Variant antibodies that bind OX40
#330Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
#331Methods for selective expansion of γδ T-cell populations and compositions thereof
#332IL-21 agonist antibodies and methods of treatment using same
#333Immunological reagents
#334Anti-OX40 antibodies and methods of using the same
#335Anti-CD40 antibodies
#336B7-H4 antibodies and methods of use thereof
#337Anti-PD-1 antibodies and methods of use thereof
#338Nucleic acid molecules encoding anti-CD40 antibodies
#339CD8 binding agents
#340Methods of treating cancer using an IL-21 agonist
#341Immunological reagents
#342Agents for treatment of claudin expressing cancer diseases
#343Fusion proteins and their related methods
#344Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR
#345Anti-PD-1 monoclonal antibody
#346Anti P2Xreceptor antibodies and fragments thereof
#347ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#348Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
#349Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
#350Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#351Epitope for switching to T2 cell and use thereof
#352Epitope for switching to T1 cell and use thereof
#353Anti-TIGIT antibodies and methods of use thereof
#354COMPOSITIONS AND METHODS FOR TREATING CANCER
#355Bispecific antibodies specifically binding to PD1 and LAG3
#356Human TNFRSF25 antibody
#357Anti-VISTA antibodies and fragments
#358Combination therapy for the treatment of cancer
#359Antibodies against TIM3 and uses thereof
#360Fully human antibody against human CD 137
#361Methods to protect transplanted tissue from rejection
#362ANTIGEN RECEPTORS AND USES THEREOF
#363ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF
#364HUMAN IMMUNE THERAPIES USING A CD27 AGONIST IN COMBINATION WITH ANOTHER IMMUNE AGONIST TO TREAT CANCER
#365Humanized or affinity-matured anti ang-2 antibody and uses thereof
#366ANTI-CD19 scFv (FMC63) POLYPEPTIDE AND USES THEREOF
#367Combination immunotherapy for the treatment of cancer
#368Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
#369Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
#370Anti-PVRIG antibodies and methods of use
#371Anti c-Met antibodies
#372ANTI-CD38 HUMAN ANTIBODIES AND USES THEREFOR
#373Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
#3744-1BB binding molecules
#375Anti-CD3 antibodies and methods of use thereof
#376Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
#377Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
#378Epitope for switching to T17 cell and use thereof
#379Anti-PD-L1 antibodies
#380Methods for expansion or depletion of t-regulatory cells
#381BTLA Antibodies and Uses Thereof
#382Antibody molecules to PD-1 and uses thereof
#383Neutralizing anti-influenza binding molecules and uses thereof
#384Polypeptides
#385IL15/IL15Rα heterodimeric Fc-fusion proteins
#386Antibodies against human NKG2D and uses thereof
#387Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
#388Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
#389Anti-HER2 antibodies and methods of use
#390Anti-ANG2 antibody
#391ANTI-H7CR ANTIBODIES
#392Anti-human vista antibodies and use thereof
#393Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#394Anti-Flt-1 antibodies for treating duchenne muscular dystrophy
#395Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
#396ANTI-H7CR ANTIBODIES
#397Anti-TIGIT antibodies
#398Nucleic acids encoding agonistic antibodies that bind CD40
#399Anti-CD89 cytotoxic complex
#400Anti-PD-1 antibodies
#401Antibodies against TIM3 and uses thereof
#402Cell penetrating antibodies
#403Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#404Methods and compositions related to modulators of eukaryotic cells
#405Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
#406BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
#407Humanized anti-CD134 (OX40) antibodies and uses thereof
#408INTERFERON ALPHA ANTIBODIES AND THEIR USES
#409C-MET ANTIBODY COMBINATIONS
#410ANTI-CD19 scFv (FMC63) POLYPEPTIDE
#411Anti-CD40 antibodies
#412MONOCLONAL ANTIBODIES AGAINST C-MET
#413Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
#414Heterodimeric antibodies that bind CD3 and PSMA
#415MONOCLONAL ANTIBODIES AGAINST C-MET
#416COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY
#417Compositions and methods of use for augmented immune response and cancer therapy
#418Antibodies against OX40 and uses thereof
#419Anti-human vista antibodies and use thereof
#420Anti-human vista antibodies and use thereof
#421Anti-human vista antibodies and use thereof
#422COMPOSITIONS AND METHODS FOR TREATING CANCER
#423Anti-OX40 antibodies and methods of using the same
#424Anti PD-1 antibodies
#425Method of identifying anti-VISTA antibodies
#426Immunological reagents
#427Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
#428Methods for improving cardiac function by administering an antibody that activates APLNR
#429Anti-PD-L1 antibodies
#430Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
#431Immune-stimulating monoclonal antibodies against human interleukin-2
#432Recombinant monovalent antibodies
#433Immunological reagents
#434IMMUNOREGULATION BY ANTI-ILTS ANTIBODIES AND ILTS-BINDING ANTIBODY FRAGMENTS
#435Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#436Method of making an anti-CD40 antibody
#437Anti-PD-L1 antibodies, compositions and articles of manufacture
#438Distinguishing antagonistic and agonistic anti B7-H1 antibodies
#439Monoclonal antibodies to programmed death 1 (PD-1)
#440Anti-PVRIG antibodies and methods of use
#441Antibodies to TGF-beta
#442APLNR modulators and uses thereof
#443Anti-vista antibodies and fragments
#444Humanized monoclonal antibodies and methods of use
#445Anti-PVRIG antibodies and methods of use
#446Interferon receptor 1 antibodies and their uses
#447Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#448Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#449Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#450Antibodies against OX40 and uses thereof
#451Anti-OX40 antibodies
#452Immunomodulatory agents
#453Humanized or chimeric CD3 antibodies
#454VISTA antagonist and methods of use
#455Agents for treatment of claudin expressing cancer diseases
#456Combination immunotherapy for the treatment of cancer
#457Anti-PVRIG antibodies and methods of use
#458Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
#459Human immune therapies using a CD27 agonist in combination with another immune agonist to treat cancer
#460Combinatorial antibody libraries and uses thereof
#461Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
#462Humanized monoclonal antibodies and methods of use
#463Molecules that bind CD180, compositions and methods of use
#464Humanized or chimeric CD3 antibodies
#465TRPM4 channel inhibitors for stroke treatment
#466Anti-PD-1 antibodies and methods of use thereof
#467Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen
#468Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#469IL-21 binding proteins
#470Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#471Anti-CD38 human antibodies and uses thereof
#472Anti-CD19 scFv (FMC63) polypeptide
#473Antagonist of the BTLA/HVEM interaction for use in therapy
#474Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#475Nucleic acid encoding anti-OX40 antibodies
#476Method of reducing blood glucose by administering RON agonists
#477Methods of modulating immune function
#478Anti-H7CR antibodies
#479Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#480Anti c-Met antibodies
#481Anti c-Met antibodies
#482Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma
#483Methods for expansion or depletion of T-regulatory cells
#484Compositions and methods for immunotherapy
#485Inert format
#486Antibodies that bind human CD27 and uses thereof
#487Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#488Humanized or affinity-matured anti Ang-2 antibody and uses thereof
#489Monoclonal antibodies against c-Met
#490Methods and compositions related to modulators of eukaryotic cells
#491Anti-OX40 antibodies and methods of using the same
#492Stem cell enhancing therapeutics
#493Antibodies to TGF-β
#494Anti P2Xreceptor antibodies and fragments thereof
#495Antibody modulators of APLNR
#496Antibody molecules to PD-1 and uses thereof
#497Anti-ILT5 antibodies and ILT5-binding antibody fragments
#498Antagonist antibodies against EphB3
#499Dimeric protein with triple mutations
#500BTLA antibodies and uses thereof
#501Anti-CD134 (OX40) antibodies and uses thereof
#502COMPOSITIONS AND METHODS FOR TREATING CANCER
#503DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IMMUNE CELL RECEPTORS AND AUTOANTIGENS
#504Use of an anti-Ang2 antibody
#505Combination therapy using c-Met inhibitor and beta-catenin inhibitor
#506GITR antigen binding proteins and methods of use thereof
#507Method of blocking vascular leakage using an anti-ANG2 antibody
#508Anti-Ang2 antibody
#509Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
#510Rationally designed antibodies
#511Methods of promoting immunity to an infectious agent by administering CD40 agonists and alpha-galactosyl ceramide
#512Humanized anti-CD134 (OX40) antibodies and uses thereof
#513Method of producing 4-1BB binding molecules and associated nucleic acids
#514Monoclonal antibodies to Programmed Death 1 (PD-1)
#515PD-1 antibodies and PD-L1 antibodies and uses thereof
#516Methods for treating cancer using anti-PD-1 antibodies
#517Combination immunotherapy for the treatment of cancer
#518Anti-OX40 antibodies and methods of treating cancer
#519Monoclonal antibodies to programmed death 1 (PD-1)
#520Anti-CD40 antibodies
#521Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#522Monovalent binding proteins
#523Methods of modulating HVEM, BTLA and CD160 cis complex response or signaling activity with soluble light polypeptide sequences
#524Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies
#525Anti c-Met antibodies
#526Methods for preparing interferon alpha antibodies
#527Anti-CD3 antibodies and methods of use thereof
#528Method for producing a multivalent fab fragment with collagen-like peptide
#529Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#530Antibodies to TGF-beta
#531VISTA modulators for diagnosis and treatment of cancer
#532Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
#533Nucleic acids related to fusion proteins
#534Antibody specifically recognizing an epitope for switching to Th2 cell and a method for converting T cell to type 2 helper T cell using the same
#535Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell
#536Antibody specifically recognizing an epitope for switching to T1 cell
#537Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
#538Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
#539Human anti-PD-1 antibodies and uses therefor
#540Anti-OX40 antibodies and methods of using the same
#541Stable Tregs and related materials and methods
#542Interferon receptor 1 antibodies and their uses
#543Monoclonal antibodies against c-Met
#544Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
#545Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
#546Bispecific T-cell activator antibody
#5474-1BB binding molecules
#548Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo
#549Agonist antibody to human thrombopoietin receptor
#550Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
#551ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
#552METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
#553METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
#554Anti-ILT5 antibodies and ILT5-binding antibody fragments
#555Compositions and Methods for Treating Inflammatory Lung Disease
#556Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#557Antibodies to c-Met
#558Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#559Anti P2X7 receptor antibodies and fragments thereof
#560CD40 ANTIBODY FORMULATION AND METHODS
#561COMPOSITIONS AND METHODS OF MONOCLONAL AND POLYCLONAL ANTIBODIES SPECIFIC FOR T CELL SUBPOPULATIONS
#562Combination immunotherapy for the treatment of cancer
#5634-1BB binding molecules
#564Methods of modulating immune function
#565USE OF A CD258 BINDING PHARMACEUTICAL SUBSTRANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT
#566ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
#567Compositions and methods of use for therapeutic antibodies
#568Toll Like Receptor 3 Antagonists, Methods and Uses
#569ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF
#570Compositions and methods of use for therapeutic antibodies
#571C-Met antibody combinations
#572Anti c-Met antibodies
#573Compositions and methods for the diagnosis and treatment of immune disorders
#574TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS
#575Superagonistic anti-CD28 antibodies
#576HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS OR RENAL DISEASE ASSOCIATED ANEMIA
#577METHOD FOR INHIBITING NEURODEGENERATION
#578Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
#579METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION
#580BTLA Antibodies and Uses Thereof
#581Combinatorial antibody libraries and uses thereof
#582Agonist antibody to human thrombopoietin receptor
#583USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
#584PD-1 antibodies and PD-L1 antibodies and uses thereof
#585Antibodies for depletion of ICOS-positive cells in vivo
#586TNFR25 AGONISTS TO ENHANCE IMMUNE RESPONSES TO VACCINES
#587Molecules that bind CD180, compositions and methods of use
#588Antibodies That Specifically Bind to DR3
#589Anti-DLL4 antibodies and uses thereof
#590Recombinant monovalent antibodies
#591Monoclonal antibody and use thereof
#592WISP polypeptides and nucleic acids encoding same
#593DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT
#594Interferon alpha antibodies and their uses
#595NOVEL ANTI-HSP90 MONOCLONAL ANTIBODY
#596Antibodies that bind human CD27 and uses thereof
#597Anti-PD-L1 antibodies and uses therefor
#598Anti-CD38 human antibodies and uses thereof
#599Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
#600Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders